Antibody-drug conjugates.
作者信息
Ornes Stephen
出版信息
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13695. doi: 10.1073/pnas.1314120110.
Abstract
摘要
相似文献
1
Antibody-drug conjugates.抗体药物偶联物
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13695. doi: 10.1073/pnas.1314120110.
2
Third-generation antibody drug conjugates for cancer therapy--a balancing act.用于癌症治疗的第三代抗体药物偶联物——一场平衡之举。
Ther Deliv. 2016;7(3):141-4. doi: 10.4155/tde-2016-0002.
3
Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.抗体药物偶联物吸收、分布、代谢和排泄特征的当前研究方法：一份行业白皮书。
Drug Metab Dispos. 2016 May;44(5):617-23. doi: 10.1124/dmd.115.068049. Epub 2015 Dec 15.
4
Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.抗体偶联药物：综述。两种已批准药物概要。
Drug Deliv. 2016 Jun;23(5):1662-6. doi: 10.3109/10717544.2014.998323. Epub 2015 Jan 27.
5
Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.为抗体药物偶联物疗法选择最佳抗体：内化作用与细胞内定位
Methods Mol Biol. 2013;1045:41-9. doi: 10.1007/978-1-62703-541-5_3.
6
Antibody-drug conjugates.抗体药物偶联物
Nat Rev Drug Discov. 2013 Apr;12(4):259-60. doi: 10.1038/nrd3980.
7
Characterization of the Primary Structure of Cysteine-Linked Antibody-Drug Conjugates Using Capillary Electrophoresis with Mass Spectrometry.采用毛细管电泳-质谱联用技术对半胱氨酸连接的抗体药物偶联物的一级结构进行表征。
Methods Mol Biol. 2020;2078:263-272. doi: 10.1007/978-1-4939-9929-3_18.
8
Pharmacokinetics and ADME characterizations of antibody-drug conjugates.抗体药物偶联物的药代动力学和药物代谢动力学特征
Methods Mol Biol. 2013;1045:117-31. doi: 10.1007/978-1-62703-541-5_7.
9
Stable and Potent Selenomab-Drug Conjugates.稳定且高效的硒单克隆抗体-药物偶联物
Cell Chem Biol. 2017 Apr 20;24(4):433-442.e6. doi: 10.1016/j.chembiol.2017.02.012. Epub 2017 Mar 16.
10
Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.通过抗体药物偶联物中原位释放叔胺和杂芳基胺实现靶向药物递送。
Nat Chem. 2016 Dec;8(12):1112-1119. doi: 10.1038/nchem.2635. Epub 2016 Oct 17.
引用本文的文献
1
Antibody-drug conjugates: smart weapons against cancer.抗体药物偶联物：对抗癌症的智能武器。
Arch Med Sci. 2019 Feb 18;16(5):1257-1262. doi: 10.5114/aoms.2019.83020. eCollection 2020.
2
How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.计算化学和药物输送技术如何支持新型抗癌药物的开发。
Molecules. 2020 Apr 10;25(7):1756. doi: 10.3390/molecules25071756.
3
Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy.优化抗体药物偶联物在癌症治疗中成功构建的挑战
Antibodies (Basel). 2018 Feb 13;7(1):11. doi: 10.3390/antib7010011.
4
Theranostics based on AIEgens.基于聚集诱导发光纳米材料的治疗策略。
Theranostics. 2018 Sep 9;8(18):4925-4956. doi: 10.7150/thno.27787. eCollection 2018.
5
Next Generation Biopharmaceuticals: Product Development.下一代生物制药：产品开发
Adv Biochem Eng Biotechnol. 2018;165:253-276. doi: 10.1007/10_2016_57.
6
Cancer-Associated, Stimuli-Driven, Turn on Theranostics for Multimodality Imaging and Therapy.癌症相关的、刺激驱动的、用于多模态成像和治疗的开启型治疗诊断一体化。
Adv Mater. 2017 Jun;29(23). doi: 10.1002/adma.201606857. Epub 2017 Mar 29.
7
Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes.受体交联：触发治疗性受体-配体复合物内化和溶酶体靶向的通用方法。
Mol Ther. 2015 Dec;23(12):1888-98. doi: 10.1038/mt.2015.178. Epub 2015 Sep 28.
8
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine's Tool Box.杂环抗癌化合物：最新进展及向纳米医学工具箱应用的范式转变
Molecules. 2015 Sep 16;20(9):16852-91. doi: 10.3390/molecules200916852.
9
Exploiting protected maleimides to modify oligonucleotides, peptides and peptide nucleic acids.利用受保护的马来酰亚胺修饰寡核苷酸、肽和肽核酸。
Molecules. 2015 Apr 10;20(4):6389-408. doi: 10.3390/molecules20046389.
10
Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.曲妥珠单抗（ado-曲妥珠单抗）的天然质谱和离子淌度表征，一种赖氨酸连接的抗体药物偶联物 。
Protein Sci. 2015 Aug;24(8):1210-23. doi: 10.1002/pro.2666. Epub 2015 Mar 31.
本文引用的文献
1
Trastuzumab emtansine for HER2-positive advanced breast cancer.曲妥珠单抗-美坦新偶联物用于治疗人表皮生长因子受体 2 阳性的晚期乳腺癌。
N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1.
2
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.一项评估 Brentuximab vedotin 治疗复发或难治性霍奇金淋巴瘤患者的关键性 II 期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.
Zotero 插件